Not an expert on this stuff but I think it likely the FDA will look at it holistically and release “all of the above.” Safety component in particular has a cross study attribute requirement. Efficacy has already been demonstrated for HIV…that partial hold in particular, which is more important for Cytodyn’s future state…is a no-brainer with a gift-wrapped cross-study safety analysis.